Utilisation of systemic therapy options in routine treatment of metastatic colorectal cancer in Australia

In the treatment of metastatic colorectal cancer (mCRC), exposure to all three active cytotoxic agents, 5‐fluorouracil/capecitabine, irinotecan and oxaliplatin, improves overall survival. The addition of biologic agents (bevacizumab and cetuximab/panitumumab) further improves survival. The uptake of available systemic agents for mCRC in routine practice in Australia is poorly described.

[1]  P. Gibbs,et al.  Chemotherapy and biologic use in the routine management of metastatic colorectal cancer in Australia: is clinical practice following the evidence? , 2019, Internal medicine journal.

[2]  J. Meyerhardt,et al.  Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial , 2017, JAMA.

[3]  P. Quirke,et al.  Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  Xianglin L. Du,et al.  Patterns of Treatment Sequences in Chemotherapy and Targeted Biologics for Metastatic Colorectal Cancer: Findings from a Large Community-Based Cohort of Elderly Patients. , 2016, Drugs - real world outcomes.

[5]  Trends in colorectal cancer admissions and stage at presentation: impact of screening , 2016, Surgical Endoscopy.

[6]  G. Fontanini,et al.  FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. , 2015, The Lancet. Oncology.

[7]  E. Van Cutsem,et al.  Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  I. Nagtegaal,et al.  Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies , 2014, Clinical Cancer Research.

[9]  J. Meyerhardt,et al.  Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer. , 2014, Journal of the National Cancer Institute.

[10]  M. Bhosle,et al.  Patterns of treatment with chemotherapy and monoclonal antibodies for metastatic colorectal cancer in Western Europe , 2012, Current medical research and opinion.

[11]  W. Scheithauer,et al.  XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results , 2011, British Journal of Cancer.

[12]  G. Hess,et al.  Systemic Therapy for Metastatic Colorectal Cancer: Patterns of Chemotherapy and Biologic Therapy Use in US Medical Oncology Practice. , 2010, Journal of oncology practice.

[13]  A. Abernethy,et al.  Longitudinal patterns of chemotherapy use in metastatic colorectal cancer. , 2009, Journal of oncology practice.

[14]  P. Gibbs,et al.  TOWARDS ESTABLISHING A NATIONAL COLORECTAL CANCER DATABASE: LESSONS LEARNT FROM BIO21 MOLECULAR MEDICINE INFORMATICS MODEL , 2008, ANZ journal of surgery.

[15]  C. Bokemeyer,et al.  Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Valerio,et al.  Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Armando Santoro,et al.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.

[18]  D. Sargent,et al.  Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  C. Tournigand,et al.  FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  C. Wilson,et al.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. James,et al.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.

[22]  J. Laurie,et al.  Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  C. Heidelberger,et al.  Fluorinated Pyrimidines, A New Class of Tumour-Inhibitory Compounds , 1957, Nature.